AstraZeneca partners with insitro on AI-driven drug discovery for MASH, cardiomyopathies
AZN•AstraZeneca and insitro entered a drug discovery and licensing collaboration to develop AI-driven treatments for MASH and cardiomyopathies. Insitro will receive $40 million upfront and could earn approximately $1.46 billion in development and commercial milestones, plus potential single-digit royalties on global sales.
1. Deal terms
AstraZeneca and insitro will collaborate on AI-driven drug discovery for MASH and cardiomyopathies. Insitro is eligible for up to approximately $1.46 billion in development and commercial milestones, in addition to $40 million upfront and potential single-digit royalties on global commercial sales. AstraZeneca will hold exclusive worldwide rights to advance selected programs identified through the collaboration.
